AU2010243213B2 - Anti-cancer drugs, and uses relating for malignant melanoma and other cancers - Google Patents

Anti-cancer drugs, and uses relating for malignant melanoma and other cancers Download PDF

Info

Publication number
AU2010243213B2
AU2010243213B2 AU2010243213A AU2010243213A AU2010243213B2 AU 2010243213 B2 AU2010243213 B2 AU 2010243213B2 AU 2010243213 A AU2010243213 A AU 2010243213A AU 2010243213 A AU2010243213 A AU 2010243213A AU 2010243213 B2 AU2010243213 B2 AU 2010243213B2
Authority
AU
Australia
Prior art keywords
compound
cancer
pharmaceutically acceptable
dimethylamino
diazenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010243213A
Other languages
English (en)
Other versions
AU2010243213A1 (en
Inventor
Venkata Krishna Raju Alluri
Kiran Bhupathiraju
Ganga Raju Gokaraju
Rama Raju Gokaraju
Venkata Kanaka Ranga Raju Gokaraju
Trimurtulu Golakoti
Sudhakar Kasina
Krishanu Sengupta
Venkateswarlu Somepalli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kasina Laila Innova Pharmaceuticals Pvt Ltd
Original Assignee
Kasina Laila Innova Pharmaceuticals Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kasina Laila Innova Pharmaceuticals Pvt Ltd filed Critical Kasina Laila Innova Pharmaceuticals Pvt Ltd
Publication of AU2010243213A1 publication Critical patent/AU2010243213A1/en
Application granted granted Critical
Publication of AU2010243213B2 publication Critical patent/AU2010243213B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/04—1,2,3-Triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D517/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains three hetero rings
    • C07D517/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2010243213A 2009-04-27 2010-04-26 Anti-cancer drugs, and uses relating for malignant melanoma and other cancers Ceased AU2010243213B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN959/CHE/2009 2009-04-27
IN959CH2009 2009-04-27
PCT/IN2010/000262 WO2010125575A1 (en) 2009-04-27 2010-04-26 Anti-cancer drugs, and uses relating for malignant melanoma and other cancers

Publications (2)

Publication Number Publication Date
AU2010243213A1 AU2010243213A1 (en) 2011-10-27
AU2010243213B2 true AU2010243213B2 (en) 2014-09-11

Family

ID=42992332

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010243213A Ceased AU2010243213B2 (en) 2009-04-27 2010-04-26 Anti-cancer drugs, and uses relating for malignant melanoma and other cancers

Country Status (11)

Country Link
US (1) US8143237B2 (enExample)
EP (1) EP2424351B1 (enExample)
JP (1) JP5571168B2 (enExample)
KR (1) KR20120006554A (enExample)
CN (1) CN102438449B (enExample)
AU (1) AU2010243213B2 (enExample)
BR (1) BRPI1006651A2 (enExample)
CA (1) CA2759519A1 (enExample)
IL (1) IL215789A0 (enExample)
NZ (1) NZ595602A (enExample)
WO (1) WO2010125575A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2640392B1 (en) * 2010-11-18 2015-01-07 Kasina Laila Innova Pharmaceuticals Private Ltd. Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
AU2011340063B2 (en) * 2010-12-09 2016-03-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
WO2012176212A1 (en) 2011-06-20 2012-12-27 V.B. Medicare Pvt. Ltd. Carrier based nanogel formulation for skin targeting.
EP2762472B1 (en) * 2011-09-28 2017-05-24 Industry-Academia Cooperation Group of Sejong University Selenophene-fused aromatic compound and manufacturing method thereof
KR101418776B1 (ko) 2011-09-28 2014-07-14 사회복지법인 삼성생명공익재단 셀레노펜-접합 방향족 화합물, 및 이의 제조 방법
WO2014012000A2 (en) 2012-07-12 2014-01-16 Euclises Pharmaceuticals, Inc. No-releasing guanidine-coxib anti-cancer agents
WO2014012074A2 (en) 2012-07-12 2014-01-16 Euclises Pharmaceuticals, Inc. No-releasing nonoate (nitrogen-bound) sulfonamide-linked-coxib anti-cancer agents
WO2014018888A1 (en) 2012-07-26 2014-01-30 Confluence Life Sciences Inc. 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as tak1 inhibitors in disease treatment
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
AU2016209046A1 (en) 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
CN108129475A (zh) * 2018-02-08 2018-06-08 中南大学湘雅三医院 一种生物光敏剂及其制备方法和应用
KR102648781B1 (ko) 2021-11-09 2024-03-19 국립공주대학교 산학협력단 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도
CN121712769A (zh) * 2023-06-29 2026-03-20 艾健科学股份有限公司 新型硒吩衍生物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029577A2 (en) * 2008-09-15 2010-03-18 Ganga Raju Gokaraju Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620804B2 (en) * 1996-06-03 2003-09-16 Purdue Research Foundation Selenophene anti-tumor agents
ATE247955T1 (de) * 1996-06-03 2003-09-15 Purdue Research Foundation Selenophen-antitumormittel
US20100183726A1 (en) 2006-08-02 2010-07-22 Robert Nicolosi Compositions and methods for treating cancer with dacarbazine nanoemulsions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029577A2 (en) * 2008-09-15 2010-03-18 Ganga Raju Gokaraju Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Also Published As

Publication number Publication date
NZ595602A (en) 2013-05-31
CA2759519A1 (en) 2010-11-04
IL215789A0 (en) 2012-01-31
BRPI1006651A2 (pt) 2015-08-25
US20100272678A1 (en) 2010-10-28
CN102438449B (zh) 2014-06-18
JP2012525329A (ja) 2012-10-22
US8143237B2 (en) 2012-03-27
HK1166591A1 (en) 2012-11-02
EP2424351B1 (en) 2015-10-21
AU2010243213A1 (en) 2011-10-27
WO2010125575A1 (en) 2010-11-04
JP5571168B2 (ja) 2014-08-13
EP2424351A1 (en) 2012-03-07
EP2424351A4 (en) 2013-04-03
CN102438449A (zh) 2012-05-02
KR20120006554A (ko) 2012-01-18

Similar Documents

Publication Publication Date Title
EP2424351B1 (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
AU2009290365B2 (en) Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
US9562060B2 (en) Heterocyclic pyridone compound, and intermediate, preparation method and use thereof
US7041685B2 (en) Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2002313633A1 (en) Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
US20150087886A1 (en) Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer
US8686146B2 (en) Azaindenoisoquinoline topoisomerase I inhibitors
CA2653654A1 (en) Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
CN1972917B (zh) 氨基嘧啶类化合物及其盐和其制备方法与药物用途
US7741488B2 (en) Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer
US9034870B2 (en) Azaindenoisoquinoline topoisomerase I inhibitors
CN114853753A (zh) 吡啶并[1,2-a]嘧啶酮类似物及其在制备FGFR抑制剂中的用途
WO2023019912A9 (zh) 苯并三嗪双氧化物及其药物组合物
HK1166591B (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
KR101762433B1 (ko) 신규한 말레인산 유도체 및 이의 제조방법 및 이를 포함하는 항암용 조성물
CN106831776A (zh) 5,10‑二氢吡啶并吡嗪并三嗪类化合物及其应用
US20090252706A1 (en) Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer
HK1154863A (en) Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired